This is reflected in the classicl breast cancer stratification into receptor-defined subtypes, termed luminal A-like, luminal B-like, triple negative breast cancer (TNBC), and human epidermal growth factor receptor 2 (HER2)-positive, as common clinical practice [5, 6]. Here, ERBB2 is linked to triple-negative breast carcinoma.